February 2 2019

Hurdles imposed by payers and high drug costs present increasing barriers to technological and precision medicine advancements in cancer programs, according to a recent survey by the Association of Community Cancer Centers.

Robert L. Ferris, MD, PhD, co-physician editor in chief of Targeted Therapies in Oncology, discusses exciting new findings and merit highlights reported in this month's issue.

Presentations at the 60th American Society of Hematology Annual Meeting & Exposition were dominated by advancements in the treatment of chronic lymphocytic leukemia.